MEGAPTH

MEGAPTH Side Effects

teriparatide

Manufacturer:

Virchow Biotech

Distributor:

Maxxcare

Marketer:

Mega Lifesciences
Full Prescribing Info
Side Effects
The following convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). The most commonly reported adverse events in patients heated with teriparatide are nausea, pain in limb, headache and dizziness. (See Tables 1, 2 and 3.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Teriparatide increases serum uric acid concentrations. However, the hyperuricemia does not result in an increase in gout, arthralgia or urolithiasis. Antibodies that cross-reacted with teriparatide were detected in women receiving teriparatide. Generally, antibodies were first detected following 12 months of treatment and diminished after withdrawal of therapy. There was no evidence of hypersensitivity reactions, allergic reactions, effects on serum calcium, or effects on bone mineral density (BMD) response.
There have been spontaneous reports of the following adverse reactions. (See Table 4.)

Click on icon to see table/diagram/image
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in